COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response [NG169], NICE (updated 9th April 2021)

The purpose of this guideline is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources. 9 April 2021, Recommendations on treatment considerations for patients not known to have COVID-19 were updated to take into account COVID-19 vaccination status.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news